I believe @ecoool2 mentioned that he was ask to write a piece, but he decided not to clog up the process as they have people attending the meeting presenting their views which has more weight than written feedback, but what @The Yankee said is very valid too
I feel that in the end this is a scientific process and the data will stand up.
It wouldn't been able to go this far without solid data - so, I'm not overly concerned about these by-plays.
Maybe, the FDA should retrospectively take the approval back for Jafaki
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-260
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |